When is Oryzon Genomics, S.A.’s U.S. patent for vafidemstat expected to expire?

Oryzon says the U.S. patent is expected to expire in March 2043, including 1,095 days of Patent Term Adjustment awarded by the USPTO for delays during patent prosecution. This estimate excludes any potential Patent Term Extension that may become available following regulatory review, if applicable.

What has happened with Oryzon Genomics, S.A.’s corresponding Canadian patent application?

A Decision to Grant has recently been issued for the corresponding Canadian patent application in the same patent family. The allowed claims cover using vafidemstat to treat non-aggressive symptoms of borderline personality disorder.

In which other countries has Oryzon Genomics, S.A. secured or been allowed corresponding patents for vafidemstat and borderline personality disorder?

Oryzon says corresponding patents have been granted or allowed in Australia, Europe, Japan, Malaysia, Mexico, Russia, Singapore and South Africa, with additional applications pending in other jurisdictions. The non-U.S. patents are expected to remain in force until at least 2040, excluding any potential patent term extensions or equivalent adjustments.

What did Oryzon Genomics, S.A.’s Chief IP Officer say about the U.S. patent?

Neus Virgili, Oryzon’s Chief IP Officer, said the U.S. patent grant, including 1,095 days of Patent Term Adjustment, significantly extends the expected patent protection for vafidemstat in borderline personality disorder. She said the Canadian notice of allowance and other granted or allowed patents strengthen Oryzon’s intellectual property position and support vafidemstat’s long-term development and commercial potential.

Does Oryzon Genomics, S.A. have a separate patent family covering aggression?

Yes. Oryzon says it separately holds a patent family directed to treating aggression and social withdrawal, with patents granted or allowed in Australia, Canada, Europe, Hong Kong, Israel, Japan, South Korea, Malaysia, the Philippines and Russia, plus additional applications pending in other jurisdictions.

What does Oryzon Genomics, S.A.’s second European patent cover?

The European Patent Office recently granted second European patent EP4512473 within the separate patent family. Oryzon says it includes specific claims covering, among others, vafidemstat for aggression associated with borderline personality disorder or autism spectrum disorder, and social withdrawal associated with schizophrenia.

How long are Oryzon Genomics, S.A.’s patents in the separate aggression and social withdrawal family expected to remain in force?

Oryzon says the patents in the separate family are expected to remain in force until at least 2038. This excludes any potential patent term extensions or adjustments.

What clinical development programmes does Oryzon Genomics, S.A. have planned for vafidemstat?

Oryzon says vafidemstat is in advanced clinical development for aggression in psychiatric disorders, with a Phase III trial in preparation for aggression in borderline personality disorder and a new Phase II trial under preparation for aggression in autism spectrum disorder. The autism spectrum disorder trial is intended to focus on genetically defined subpopulations, particularly individuals with Phelan-McDermid syndrome.

What Oryzon Genomics, S.A. trial is currently ongoing for vafidemstat?

A Phase II trial is ongoing in schizophrenia, with a focus on negative symptoms, of which Oryzon identifies social withdrawal as one of the most prominent. The announcement does not provide further trial results.

What does Oryzon Genomics, S.A. do and which identifiers does it use?

Oryzon describes itself as a clinical-stage biopharmaceutical company and global leader in epigenetics. The announcement gives its ISIN Code as ES0167733015 and its ticker symbol as ORY.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon reports U.S. patent grant covering vafidemstat in non-aggressive BPD symptoms

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon reports U.S. patent grant covering vafidemstat in non-aggressive BPD symptoms

Q: What does Oryzon Genomics, S.A.’s new U.S. patent cover?

The granted U.S. claims cover treating non-aggressive symptoms of borderline personality disorder using LSD1 inhibitors, including vafidemstat. The patent complements Oryzon’s existing patent portfolio covering the treatment of aggression.

Published Wednesday, 08 July 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Regulatory approval
Published: Wednesday, 08 July 2026
Source announcement: oryzon.com

Key figures
Measure	Figure
Patent Term Adjustment (PTA)	1,095 days

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ORY) announced that the USPTO granted a U.S. patent covering vafidemstat treatment for non-aggressive BPD symptoms.

U.S. Patent No. 12,673,044 claims non-aggressive BPD treatment using LSD1 inhibitors, including vafidemstat, complementing Oryzon’s aggression portfolio.
The company expects expiration in March 2043, including 1,095 days for prosecution delays; potential extension, if applicable, after regulatory review is excluded.
Canada issued a recent Decision to Grant for a corresponding application, with allowed claims covering vafidemstat for non-aggressive BPD symptoms.
The company expects non-U.S. patents to remain in force until at least 2040, excluding potential extensions or equivalent adjustments.

EPO patent EP4512473 covers aggression in BPD or ASD and social withdrawal in schizophrenia.

Investor FAQs

Oryzon Genomics, S.A. announced that the United States Patent and Trademark Office had granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The patent covers methods of treating non-aggressive symptoms of borderline personality disorder using LSD1 inhibitors, including vafidemstat.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON announces U.S. patent grant for vafidemstat in borderline personality disorder (BPD)
Published: Wednesday, 08 July 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…